home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »

portfolio

$47 million

Drug Delivery

Feb2Corium Prices Follow-On Offering of Common Stock »

Aug5Corium Prices Follow-On Offering of Common Stock »

Apr28Aequus and Corium Enter Into Product Development Collaboration Focused on CNS »

Dec4Corium Announces Closing Of Expanded Term Loan Facility With CRG »

Apr3
Corium International, Inc. Announces Pricing of Initial Public Offering »

MENLO PARK, Calif., April 3, 2014 -- Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today the pricing of its initial public offering of 6,500,000 shares of common stock at a price to the public of $8.00 per share. The shares are scheduled to begin trading on the NASDAQ Stock Market on April 3, 2014 under the symbol "CORI". All of the shares of common stock are being offered by Corium. Corium has also granted the underwriters a 30-day option to purchase up to 975,000 additional shares of common stock at the initial public offering price.

 

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and FBR Capital Markets & Co. are acting as co-managers.

 

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 2, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

The offering was made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at prospectus_department@jefferies.com; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, or by email at syndicate@leerink.com.

 

Investor and Media Contact:

Karen L. Bergman

BCC Partners

kbergman@bccpartners.com

(650) 575-1509

Dec4Corium International and Capital Royalty Close Financing Transaction »